Bio-Techne Co. (NASDAQ:TECH) Director Buys $105,765.00 in Stock

Bio-Techne Co. (NASDAQ:TECHGet Rating) Director Robert V. Baumgartner purchased 300 shares of the business’s stock in a transaction on Tuesday, May 10th. The stock was bought at an average cost of $352.55 per share, with a total value of $105,765.00. Following the purchase, the director now owns 10,106 shares in the company, valued at $3,562,870.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:TECH opened at $338.67 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.03 and a current ratio of 3.56. Bio-Techne Co. has a fifty-two week low of $337.90 and a fifty-two week high of $543.85. The firm has a market cap of $13.31 billion, a PE ratio of 61.80, a price-to-earnings-growth ratio of 2.11 and a beta of 1.24. The business has a 50 day moving average price of $411.79 and a 200-day moving average price of $437.38.

Bio-Techne (NASDAQ:TECHGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.14. The business had revenue of $290.40 million during the quarter, compared to analysts’ expectations of $279.27 million. Bio-Techne had a net margin of 20.95% and a return on equity of 16.82%. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.61 EPS. Research analysts predict that Bio-Techne Co. will post 6.81 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 27th. Investors of record on Monday, May 16th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, May 13th. This represents a $1.28 dividend on an annualized basis and a yield of 0.38%. Bio-Techne’s dividend payout ratio is presently 23.36%.

Several research analysts recently issued reports on the stock. Robert W. Baird cut their target price on shares of Bio-Techne from $520.00 to $500.00 in a research report on Thursday, May 5th. SVB Leerink increased their price objective on Bio-Techne from $530.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, February 2nd. KeyCorp dropped their target price on Bio-Techne from $600.00 to $500.00 in a research report on Thursday, May 5th. Zacks Investment Research cut shares of Bio-Techne from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, StockNews.com started coverage on shares of Bio-Techne in a report on Thursday, March 31st. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $501.29.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal London Asset Management Ltd. increased its stake in shares of Bio-Techne by 92.2% during the fourth quarter. Royal London Asset Management Ltd. now owns 9,120 shares of the biotechnology company’s stock valued at $4,721,000 after buying an additional 4,375 shares during the period. DekaBank Deutsche Girozentrale lifted its position in shares of Bio-Techne by 24.0% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 4,289 shares of the biotechnology company’s stock worth $2,121,000 after purchasing an additional 831 shares during the period. WMS Partners LLC boosted its stake in shares of Bio-Techne by 43.2% during the 3rd quarter. WMS Partners LLC now owns 2,138 shares of the biotechnology company’s stock valued at $1,036,000 after purchasing an additional 645 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its position in shares of Bio-Techne by 5.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,669 shares of the biotechnology company’s stock valued at $1,898,000 after buying an additional 182 shares during the period. Finally, CIBC Asset Management Inc lifted its holdings in Bio-Techne by 140.0% in the third quarter. CIBC Asset Management Inc now owns 3,449 shares of the biotechnology company’s stock worth $1,671,000 after buying an additional 2,012 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.

Bio-Techne Company Profile (Get Rating)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Featured Articles

Insider Buying and Selling by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.